IPO News Archive
Seattle-based biotech Omeros sets IPO terms

9/16/09


Omeros, which a biotech company focused on inflammation/pain and disorders of the central nervous system, announced terms for its IPO on Wednesday. The Seattle, WA-based company, which was founded in 1994, plans to raise $75 million by offering 6,820,000 at a price range of $10.00 to $12.00. At the mid-point of the proposed range, Omeros will command a market value of $260 million. Omeros plans to list on the NASDAQ under the symbol OMER. Deutsche Bank and Wedbush PacGrow Life Scienses are the lead underwriters on the deal.

If successful, Omeros will become the first pure-play biotech company to go public in the US since BioHeart (BHRT) completed an IPO in February 2008.

View IPO Profile: OMER    BHRT      
Source: www.RenaissanceCapital.com
Latest User Comments

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest